Daveen Chopra - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TMTT
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2024
Net transactions value
-$222,618
Form type
4
Filing time
06 May 2024, 19:17:52 UTC
Previous filing
21 Feb 2024
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability $24,752 -291 -1.3% $85.06 22,459 03 May 2024 Direct
transaction EW Common Stock Options Exercise $0 +4,713 +21% $0.000000 27,172 04 May 2024 Direct F1
transaction EW Common Stock Tax liability $197,865 -2,321 -8.5% $85.25 24,851 04 May 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -4,713 -100% $0.000000* 0 04 May 2024 Common Stock 4,713 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.